[ACST] Acasti Pharma, Inc.
Overview
Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 14.14 M
Exchange: NASDAQ
The data is delayed by 15 minutes.
Strongest Trends Summary For ACST
ACST is in the long-term down -98% below S&P in 11 years.
Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max
Chart type: absolute | relative to S&P
Description: Acasti Pharma Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of therapies for abnormalities in blood lipids, and the treatment and prevention of various cardiometabolic disorders in Canada and the United States. The company offers Onemia, a medical food that is used in the dietary management of illnesses associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. Its product development pipeline includes CaPre, a drug product candidate that is in Phase II clinical trials for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.
See how to gain 20% in 14 sec with TrendsInvesting
Fundamental Ratios
| Shares Outstanding | 10.71 M | EPS | EPS Growth - 4 Quarters | EPS Growth - Q/Q | |||
| EPS Growth - Y/Y | Sales Growth - 4 Quarters | Sales Growth - Q/Q | P/E | ||||
| P/E To EPS Growth | P/S | P/BV | Price/Cash Per Share | ||||
| Price/Free Cash Flow | ROA | ROE | ROI | ||||
| Current Ratio | Quick Ratio | Long Term Debt/Equity | Debt Ratio | ||||
| Gross Margin | Operating Margin | Net Profit Margin | Dividend Payout Ratio | ||||
| Dividend Yield |
Fundamental Data
| Cash From Financing Activities | Cash From Investing Activities | Cash From Operating Activities | Gross Profit | ||||
| Net Profit | Operating Profit | Total Assets | Total Current Assets | ||||
| Total Current Liabilities | Total Debt | Total Liabilities | Total Revenue |
Technical Data
| High 52 week | 3.1 | Low 52 week | 0.63 | Last close | 0.71 | Last change | 1.59% |
| RSI | 36.35 | Average true range | 0.04 | Beta | 0.3 | Volume | 4.94 M |
| Simple moving average 20 days | -2.49% | Simple moving average 50 days | -23.16% | Simple moving average 200 days | -39.8% |
Performance Data
| Performance Week | 7.92% | Performance Month | -34.26% | Performance Quart | -31.73% | Performance Half | -44.96% |
| Performance Year | -43.2% | Performance Year-to-date | -24.69% | Volatility daily | 6.55% | Volatility weekly | 14.65% |
| Volatility monthly | 30.03% | Volatility yearly | 104.04% | Relative Volume | 5202.7% | Average Volume | 196.58 K |
| New High | New Low |
News
2020-02-14 11:41:45 | Risks Remain, but Amarin Stock Is a Buy at Today’s Prices
2020-02-14 08:00:10 | Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2020
2020-02-13 09:00:10 | Acasti Pharma Schedules Third Quarter Fiscal 2020 and Business Update Conference Call
2020-02-11 11:27:42 | 3 Beaten-Down Biotech Stocks With +50% Upside Potential
2020-02-11 07:23:06 | The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology
2020-02-10 07:00:10 | Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3 Trials of CaPre
2020-01-17 11:07:12 | Does Acasti Stock Have a Future?
2020-01-17 06:30:07 | Why Amarin Stock Is Poised for a Healthy 2020
2020-01-14 09:46:02 | AstraZeneca to End Phase III Study on Fish Oil Heart Drug
2020-01-14 07:55:40 | The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug
2020-01-13 16:22:46 | This Biotech Stock Is Flying High After Rival Heart Drugs Stumbled
2020-01-13 14:31:00 | Amarin's stock surges, as rival drugs from AstraZeneca, Acasti disappoint
2020-01-13 13:38:00 | Neptune Provides Updates on Non-Core Investments
2020-01-13 11:07:00 | Amarin Stock Is Surging as Rival Makers of Fish-Oil Heart Drugs Fall Short
2020-01-13 09:40:46 | This Biotech Stock Is Flying High After Rival Heart Drugs Stumbled
2020-01-13 06:00:10 | Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre
2020-01-10 10:59:53 | All Bets Are Off for Amarin Stock
2020-01-09 08:56:44 | 3 Healthcare Stocks With Big Catalysts in January
2019-12-24 09:51:09 | Acasti Delays Data Readout For Drug To Treat Elevated Triglycerides
2019-12-24 08:13:19 | Benzinga Pro's Top 5 Stocks To Watch For Tues., Dec. 24, 2019: TSLA, WCC, ACST, YMAB, ITCI
2019-12-24 07:24:51 | The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict
2019-12-23 20:31:15 | Acasti Pharma Provides Update on Timing of Topline Results for TRILOGY 1 Phase 3 Trial of CaPre
2019-12-22 16:43:00 | Hedge Funds Have Never Been This Bullish On Acasti Pharma Inc. ACST
2019-12-20 04:41:30 | Amarin Stock is at Sky-High Levels Already Assumes All the Good News
2019-11-26 07:55:10 | Acasti Pharma Reports Last Patient Visit in TRILOGY 1 Phase 3 Trial of CaPre for the Treatment of Severe Hypertriglyceridemia
2019-11-25 08:30:00 | Encode Ideas, L.P. Announces the Initiation of Research Coverage on Acasti Pharma, Inc.
2019-11-21 08:23:01 | Amarin's Shares Down on Underperform Rating by Oppenheimer
2019-11-18 08:38:28 | Acasti Pharma Releases Preliminary New Animal Data, and Gains Insights Into CaPre’s Novel Mechanism of Action in Diabetes
2019-11-13 07:55:00 | Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2020
2019-11-07 08:30:00 | Acasti Pharma Announces Publication of CaPre Pharmacokinetics Study in a Leading Peer-Reviewed Journal
2019-11-06 09:00:00 | Acasti Pharma Schedules Second Quarter Fiscal 2020 Conference Call
2019-11-04 09:04:06 | Acasti Pharma Partners with Aker BioMarine to Supply Krill Oil for CaPre®
2019-10-01 09:00:00 | Acasti Pharma to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
2019-09-30 08:35:00 | Acasti Pharma Announces Additional Phase 3 Milestones Reached, and Remains on Track to Report Topline Results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020
2019-09-27 06:05:30 | Do Insiders Own Lots Of Shares In Acasti Pharma Inc. CVE:ACST?
2019-09-09 08:30:00 | Acasti Pharma Receives Funding from the Government of Canada to Expand Production Capacity
2019-09-04 09:00:00 | Acasti Pharma to Present at the 21st Annual Rodman & Renshaw Global Investment Conference in New York City on September 9th
2019-08-28 16:05:00 | Acasti Pharma Announces the Election of Its Directors, Amendments to Its Stock Option and Equity Incentive Plans and Other Related Matters Approved at Its AGM
2019-08-14 08:00:00 | Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2020
2019-08-09 08:00:00 | Acasti Pharma Co-Founder, Chief Operating and Scientific Officer to Participate on Lipid Panel at the 2019 BTIG Biotechnology Conference
2019-08-07 08:00:00 | Acasti Pharma Schedules First Quarter Fiscal 2020 Conference Call
2019-07-25 15:42:52 | Acasti Pharma Comments on Trading Activity and Reaffirms No Plans to Raise Capital
2019-07-05 08:35:12 | Bausch Gains 38.9% YTD on Product Launches & Debt Reduction
2019-06-26 11:08:45 | Acasti Pharma Trades Higher Despite 'Material Uncertainty'
2019-06-26 11:00:00 | Acasti Pharma, Inc. to Host Earnings Call
2019-06-26 08:05:00 | Acasti Pharma Provides Fiscal 2019 Year-End Business Update
2019-06-24 09:00:00 | Acasti Pharma Awarded Notice of Allowance for a Second Patent in China Covering CaPre’s Omega-3 Phospholipid Composition
2019-06-19 08:00:00 | Acasti Pharma Schedules Fourth Quarter and Fiscal 2019 Conference Call
2019-06-04 09:15:00 | Acasti Pharma Announces TRILOGY 2 Trial Has Achieved its 100% Patient Randomization Target in Patients with Severe Hypertriglyceridemia
2019-05-23 17:00:00 | Acasti Issues Shares in Settlement of Claims with Former Chief Executive Officer